Cargando…

Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer

Randomized controlled trial of adjuvant chemoimmunotherapy for lung cancer indicated a significant advantage in patients receiving immunotherapy. Herein we report the final results and immunological analysis with a median follow-up of 59.6 months. Patients with post-surgical lung cancer were randoml...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Hideki, Matsui, Yukiko, Ishikawa, Aki, Nakajima, Takahiro, Iizasa, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097784/
https://www.ncbi.nlm.nih.gov/pubmed/29855695
http://dx.doi.org/10.1007/s00262-018-2180-6
_version_ 1783348366127661056
author Kimura, Hideki
Matsui, Yukiko
Ishikawa, Aki
Nakajima, Takahiro
Iizasa, Toshihiko
author_facet Kimura, Hideki
Matsui, Yukiko
Ishikawa, Aki
Nakajima, Takahiro
Iizasa, Toshihiko
author_sort Kimura, Hideki
collection PubMed
description Randomized controlled trial of adjuvant chemoimmunotherapy for lung cancer indicated a significant advantage in patients receiving immunotherapy. Herein we report the final results and immunological analysis with a median follow-up of 59.6 months. Patients with post-surgical lung cancer were randomly designated to receive either chemoimmunotherapy (group A, immunotherapy arm) or chemotherapy (group B, control arm). The immunotherapy comprised the adoptive transfer of autologous activated killer T cells and dendritic cells (AKT–DC). The 2- and 5-year overall survival (OS) rates were 96.0 and 69.4% in group A and 64.7 and 45.1% in group B, respectively. Multivariate analysis results revealed that the hazard ratio was 0.439. The 2- and 5-year recurrence-free survival rates were 70.0 and 57.9% in group A and 43.1 and 31.4% in group B, respectively. Subgroup analysis for the OS between treatment groups indicated that younger patients (≤ 55 years: HR 0.098), males (HR 0.474), patients with adenocarcinoma (HR 0.479), patients with stage III cancer (HR 0.399), and those who did not receive preoperative chemotherapy (HR 0.483) had lower HRs than those in the other groups. Immunological analysis of cell surface markers in regional lymph nodes of subjects receiving immunotherapy indicated that the CD8(+)/CD4(+) T-cell ratio was elevated in survivors. Patients with non-small-cell lung cancer benefited from adoptive cellular immunotherapy as an adjuvant to surgery. Patients with stage III cancer, those with adenocarcinoma, and those not receiving preoperative chemotherapy were good candidates. Lastly, cytotoxic T cells were important for a favorable chemoimmunotherapy outcome.
format Online
Article
Text
id pubmed-6097784
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-60977842018-08-24 Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer Kimura, Hideki Matsui, Yukiko Ishikawa, Aki Nakajima, Takahiro Iizasa, Toshihiko Cancer Immunol Immunother Original Article Randomized controlled trial of adjuvant chemoimmunotherapy for lung cancer indicated a significant advantage in patients receiving immunotherapy. Herein we report the final results and immunological analysis with a median follow-up of 59.6 months. Patients with post-surgical lung cancer were randomly designated to receive either chemoimmunotherapy (group A, immunotherapy arm) or chemotherapy (group B, control arm). The immunotherapy comprised the adoptive transfer of autologous activated killer T cells and dendritic cells (AKT–DC). The 2- and 5-year overall survival (OS) rates were 96.0 and 69.4% in group A and 64.7 and 45.1% in group B, respectively. Multivariate analysis results revealed that the hazard ratio was 0.439. The 2- and 5-year recurrence-free survival rates were 70.0 and 57.9% in group A and 43.1 and 31.4% in group B, respectively. Subgroup analysis for the OS between treatment groups indicated that younger patients (≤ 55 years: HR 0.098), males (HR 0.474), patients with adenocarcinoma (HR 0.479), patients with stage III cancer (HR 0.399), and those who did not receive preoperative chemotherapy (HR 0.483) had lower HRs than those in the other groups. Immunological analysis of cell surface markers in regional lymph nodes of subjects receiving immunotherapy indicated that the CD8(+)/CD4(+) T-cell ratio was elevated in survivors. Patients with non-small-cell lung cancer benefited from adoptive cellular immunotherapy as an adjuvant to surgery. Patients with stage III cancer, those with adenocarcinoma, and those not receiving preoperative chemotherapy were good candidates. Lastly, cytotoxic T cells were important for a favorable chemoimmunotherapy outcome. Springer Berlin Heidelberg 2018-05-31 2018 /pmc/articles/PMC6097784/ /pubmed/29855695 http://dx.doi.org/10.1007/s00262-018-2180-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Kimura, Hideki
Matsui, Yukiko
Ishikawa, Aki
Nakajima, Takahiro
Iizasa, Toshihiko
Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title_full Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title_fullStr Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title_full_unstemmed Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title_short Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
title_sort randomized controlled phase iii trial of adjuvant chemoimmunotherapy with activated cytotoxic t cells and dendritic cells from regional lymph nodes of patients with lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097784/
https://www.ncbi.nlm.nih.gov/pubmed/29855695
http://dx.doi.org/10.1007/s00262-018-2180-6
work_keys_str_mv AT kimurahideki randomizedcontrolledphaseiiitrialofadjuvantchemoimmunotherapywithactivatedcytotoxictcellsanddendriticcellsfromregionallymphnodesofpatientswithlungcancer
AT matsuiyukiko randomizedcontrolledphaseiiitrialofadjuvantchemoimmunotherapywithactivatedcytotoxictcellsanddendriticcellsfromregionallymphnodesofpatientswithlungcancer
AT ishikawaaki randomizedcontrolledphaseiiitrialofadjuvantchemoimmunotherapywithactivatedcytotoxictcellsanddendriticcellsfromregionallymphnodesofpatientswithlungcancer
AT nakajimatakahiro randomizedcontrolledphaseiiitrialofadjuvantchemoimmunotherapywithactivatedcytotoxictcellsanddendriticcellsfromregionallymphnodesofpatientswithlungcancer
AT iizasatoshihiko randomizedcontrolledphaseiiitrialofadjuvantchemoimmunotherapywithactivatedcytotoxictcellsanddendriticcellsfromregionallymphnodesofpatientswithlungcancer